Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to address unmet medical needs. Daiichi Sankyo draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. The 2025 Vision is to become a “Global Pharma Innovator with Competitive Advantage in Oncology”, focusing on novel therapies in oncology, including immuno-oncology.
For more information, please visit: www.daiichisankyo.com.
Content provided by sponsor:
- ESMO 2014 Poster: Phase 3 study of patritumab plus erlotinib in EGFR wild-type subjects with advanced non–small cell lung cancer
- ESMO 2014 Poster: Efficacy of patritumab (U3-1287), a fully human anti–human epidermal growth factor receptor 3 (HER3) monoclonal antibody, in head and neck cancer models
The European Society for Medical Oncology (ESMO) wishes to thank Daiichi Sankyo for donating this content.
ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.